Johan D. Aasbo, DO; Richard G. Trohman, MD
Potential Financial Conflicts of Interest: Consultancies: R.G. Trohman (Guidant CRM Business Strategy Advisory Board); Honoraria: R.G. Trohman (St. Jude Medical, Inc., Guidant CRM); Grants received: R.G. Trohman (St. Jude Medical, Inc., Medtronic, Inc., Guidant CRM, Wyeth-Ayerst).
Aasbo JD, Trohman RG. Amiodarone Prophylaxis. Ann Intern Med. 2006;144:303. doi: 10.7326/0003-4819-144-4-200602210-00016
Download citation file:
Published: Ann Intern Med. 2006;144(4):303.
We agree with Mr. Craycraft's observation that similar cohort data were presented in the studies by Giri and associates (1) and by White and associates (2), both of which were included in our meta-analysis. The number of stroke end points (16 in Giri, 9 in White), the percentage of patients who received β-blockers (72.4% in Giri vs. 89.1% in White), and the percentage of patients who had valvular surgery (26.9% in Giri vs. 18.2% in White) are different in the 2 papers. Although the Annals of Thoracic Surgery identified the publication by White and colleagues as an “Original Article,” in retrospect, it appeared likely (to us) that the authors reported a substudy (rather than a duplicate) of AFIST (Atrial Fibrillation Suppression Trial). We spoke directly to Dr. White on 14 December 2005. He confirmed that the Annals of Thoracic Surgery article was a substudy of AFIST and that the same patient population was used.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only